Abstract：
Aim: To systematically review the cases of anosmia or ageusia after receiving the coronavirus disease 2019 (COVID-19) vaccine. Methods: A systematic search was conducted in electronic databases, including Web of Science, Scopus, Embase, and PubMed, to identify any published study that evaluated the anosmia or ageusia after receiving the COVID-19 vaccine, including case reports, case series, letter to editor articles with reported cases regarding our topic, or observational studies with at least 1 eligible patient consisted with our criteria. We excluded the studies that reported anosmia or ageusia due to COVID-19 infection and non-COVID-19 vaccines. Results: Five studies consisting of 11 patients were included in this systematic review. Of the 11 patients, 5 patients had received the Pfizer COVID-19 vaccine and 6 patients received the Oxford-AstraZeneca COVID-19 vaccine, of which 6 patients developed symptoms after the first dose of vaccination and 5 patients were symptomatic after the second vaccine dose. Most of the patients developed symptoms within 1 week after the vaccination. The disorders of the patients included partial or total anosmia, parosmia, phantosmia, hyposmia, ageusia, and dysgeusia. Also, the patients had symptoms other than smell or taste disorders, including arthralgia, fever, chills, rhinorrhea, myalgia, abdominal pain, fatigue, muscle weakness, altered bowel pattern, aural fullness, tinnitus, and headache. Most of the evaluated patients did not receive any treatment as for their disorders. However, in some cases, treatment with oral corticosteroids or dietary supplementation was required. Conclusion: Anosmia and ageusia are important symptoms of COVID-19 vaccination. These symptoms will resolve without any treatment in most cases, although some interventions may be needed in some patients.
摘要：
目的：系统回顾接受2019年冠状病毒病（COVID-19）疫苗后的失语症或失语症病例。方法:在电子数据库中进行系统检索,包括WebofScience,Scopus,Embase,和PubMed,为了确定任何已发表的评估接受COVID-19疫苗后的失语症或失语症的研究，包括病例报告,案例系列,给编辑文章的信，报道了关于我们主题的案例，或对至少1名符合条件的患者进行的观察性研究符合我们的标准.我们排除了报道由于COVID-19感染和非COVID-19疫苗引起的无语症或失语症的研究。结果：本系统评价纳入了由11例患者组成的5项研究。在11名患者中，5名患者接受了辉瑞COVID-19疫苗，6名患者接受了牛津-阿斯利康COVID-19疫苗，其中6例患者在第一剂疫苗接种后出现症状，5例患者在第二剂疫苗接种后出现症状。大多数患者在接种疫苗后1周内出现症状。患者的疾病包括部分或完全的无嗅觉症，parosmia,幻影症,失足,Ageusia,和味觉障碍。此外，患者有嗅觉或味觉障碍以外的症状，包括关节痛,发烧,发冷,鼻漏,肌痛，腹痛,疲劳,肌肉无力,改变了肠道模式，听觉丰满，耳鸣,和头痛。大多数被评估的患者没有接受任何治疗。然而,在某些情况下,需要口服皮质类固醇或膳食补充剂治疗.结论：厌食症和失语是COVID-19疫苗接种的重要症状。在大多数情况下，这些症状会在没有任何治疗的情况下消失，尽管某些患者可能需要一些干预措施。
